Cardica, Inc. (Nasdaq: CRDC) announced that the full results of the PAS-Port system multi-center pivotal trial, known as the EPIC trial, were published in the July issue of the peer-reviewed publication The Journal of Thoracic and Cardiovascular Surgery. The PAS-Port system, which received 510(k) clearance from the U.S. Food and Drug Administration (FDA) in September 2008, creates a secure connection, or anastomosis, between a vein graft and the aorta, the main artery in the human body, during coronary artery bypass grafting (CABG) procedures.